Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-021187
Filing Date
2025-07-28
Accepted
2025-07-28 17:17:42
Documents
11
Period of Report
2025-07-28

Document Format Files

Seq Description Document Type Size
1 PRE 14A formpre14a.htm PRE 14A 521358
2 EX-1 ex1.htm EX-1 2634
3 EX-2 ex2.htm EX-2 79772
4 EX-3 ex3.htm EX-3 80473
5 EX-4 ex4.htm EX-4 74361
6 EX-5 ex5.htm EX-5 74389
7 EX-6 ex6.htm EX-99 21467
8 EX-7 ex7.htm EX-7 161911
9 GRAPHIC formpre14a_001.jpg GRAPHIC 3993
10 GRAPHIC proxy_001.jpg GRAPHIC 322208
11 GRAPHIC proxy_002.jpg GRAPHIC 171684
  Complete submission text file 0001641172-25-021187.txt   1667094
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-21617 | Film No.: 251156659
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)